Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Bullboard Posts
Comment by MBAon Sep 05, 2019 10:11pm
161 Views
Post# 30100792

RE:RE:Stock trades wierd

RE:RE:Stock trades wierdretiredcf, I have to disagree. There may be low volume however there was significant volume which brought the sp down from $10 after the Q2 numbers came out. The market was clearly not pleased with the miss on the EBITDA numbers (2 quarters in a row) relative to managements guidance of around 26% of revenues. Yes, they make some investments towards continued and possibly "ramped up" growth, however the guidance given to shareholders was that we could expect EBITDA to continue around 26%. In the end, the annual EBITDA numbers may hit around $21 million US which is lower than the expected numbers (including my estimates based on management's guidance). Given the misses, it is a wait and show me story for now. I think the market will now want to see how the Q3 and Q4 EBITDA numbers come out. As such, it may be a slow trading period for a few months now.
Bullboard Posts